cidofovir anhydrous has been researched along with efavirenz in 10 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (20.00) | 29.6817 |
2010's | 7 (70.00) | 24.3611 |
2020's | 1 (10.00) | 2.80 |
Authors | Studies |
---|---|
Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E | 1 |
Balzarini, J; Brancale, A; Cirilli, R; Coluccia, A; Giordano, C; La Regina, G; La Torre, F; Lavecchia, A; Maga, G; Novellino, E; Piscitelli, F; Samuele, A; Sansone, A; Silvestri, R; Zanoli, S | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
Andrei, G; Babkov, DA; Balzarini, J; Gavryushov, SA; Ivanov, AV; Khandazhinskaya, AL; Kochetkov, SN; Novikov, MS; Pannecouque, C; Paramonova, MP; Seley-Radtke, KL; Snoeck, R; Valuev-Elliston, VT | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Briguglio, I; Carta, A; Corona, P; Farci, P; Giliberti, G; Ibba, C; La Colla, P; Loddo, R; Loriga, M; Paglietti, G; Piras, S; Sanna, G | 1 |
Briguglio, I; Carta, A; Corona, P; Farci, P; Fermeglia, M; Gavini, E; Giliberti, G; Giunchedi, P; Ibba, C; La Colla, P; Laurini, E; Loddo, R; Piras, S; Pricl, S; Sanna, G | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
2 review(s) available for cidofovir anhydrous and efavirenz
Article | Year |
---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
8 other study(ies) available for cidofovir anhydrous and efavirenz
Article | Year |
---|---|
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Topics: Anti-Infective Agents; Antiviral Agents; Artificial Intelligence; Computer Simulation; Drug Evaluation, Preclinical; Molecular Structure; Quantitative Structure-Activity Relationship | 2009 |
Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
Topics: Amino Acids; Animals; Anti-HIV Agents; Antineoplastic Agents; Antiviral Agents; Cell Line, Tumor; Cell Proliferation; Cytostatic Agents; Drug Resistance, Viral; Enterovirus B, Human; HIV Reverse Transcriptase; HIV-1; Humans; Hydrophobic and Hydrophilic Interactions; Indoles; Lymphocytes; Mice; Models, Molecular; Molecular Conformation; Mutation; Protein Binding; Reverse Transcriptase Inhibitors; Stereoisomerism; Structure-Activity Relationship; Sulfones; Virus Replication | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
N1,N3-disubstituted uracils as nonnucleoside inhibitors of HIV-1 reverse transcriptase.
Topics: Binding Sites; Cell Line; Cinnamates; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Mutation; Protein Structure, Tertiary; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Uracil | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Synthesis and antiviral activity of new phenylimidazopyridines and N-benzylidenequinolinamines derived by molecular simplification of phenylimidazo[4,5-g]quinolines.
Topics: Aminoquinolines; Animals; Antiviral Agents; Cattle; Cell Line; Cell Survival; DNA Viruses; Dogs; Dose-Response Relationship, Drug; Humans; Imidazoles; Microbial Sensitivity Tests; Molecular Structure; Pyridines; RNA Viruses; Structure-Activity Relationship | 2014 |
Synthesis, cytotoxicity and antiviral evaluation of new series of imidazo[4,5-g]quinoline and pyrido[2,3-g]quinoxalinone derivatives.
Topics: Antiviral Agents; DNA Viruses; Dose-Response Relationship, Drug; Humans; Imidazoles; Microbial Sensitivity Tests; Molecular Structure; Pyridines; Quinolines; Quinoxalines; RNA Viruses; Structure-Activity Relationship | 2015 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |